Thalia Shoshana Field

Dr. Thalia Shoshana Field is an Associate Professor in the Department of Medicine - Neurology at the University of British Columbia's Faculty of Medicine, where she holds the Sauder Family/Heart and Stroke Foundation Professorship of Stroke Research. She serves as a Stroke Neurologist with the Vancouver Stroke Program based at Vancouver General Hospital, providing specialized care for patients with stroke and cerebrovascular diseases while leading important research initiatives.

Dr. Field's research focuses on clinical trials and stroke in younger adults, with particular emphasis on cerebral venous thrombosis (CVT) and adults with congenital heart disease. Her work centers on clinical trial process improvement, including optimizing participant recruitment and retention, efficient resource utilization, and selecting patient-relevant outcomes. She actively investigates how technology can address clinical trial challenges, with specific interests in telemedicine for remote participant assessment and artificial intelligence applications for trial population enrichment, automated participant assessments, and identifying patient-centered outcomes.

Analysis of her recent publications reveals a strong focus on cerebral venous thrombosis, stroke treatment protocols, and anticoagulation therapies. Her research spans from developing clinical guidelines to conducting randomized controlled trials examining novel treatment approaches for stroke and related conditions. The publications demonstrate her leadership in advancing evidence-based practices in stroke neurology and her commitment to improving clinical trial methodology.

Dr. Field serves as Principal Investigator for the SECRET trial and parallel registry examining treatment strategies for CVT, and leads a national longitudinal study investigating brain health in children and adults with congenital heart disease. She is actively involved in multiple clinical trials including studies on colchicine for vascular event prevention, NA-1 for endovascular thrombectomy patients, TNK-tPA for minor ischemic stroke, and rivaroxaban for secondary stroke prevention.

As part of the Vancouver Stroke Program, Dr. Field contributes to educating medical trainees at all levels, from medical students to fellows, who rotate through the VGH Stroke Service and Stroke Prevention Clinic. The program maintains an active research profile with a focus on investigator-initiated studies and participation in multicenter clinical trials for acute stroke and secondary prevention.